Plant Name: Uncaria africana
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; ADRA2C; ADRA2A; ADRA2B; | |
| GAA; | |
| FAAH; TDP1; TERT; CBR1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; | |
| CDK6; | |
| CA2; CA12; CA1; CA9; CA14; CA7; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| NR1I2; | |
| PTGS1; XDH; | |
| HIF1A; | |
| ABCG2; | |
| NPC1; LMNA; FABP5; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.053E-14 | 1.053E-10 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.135E-14 | 1.113E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.575E-13 | 3.737E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.290E-12 | 1.561E-09 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.736E-12 | 1.890E-09 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.302E-12 | 7.237E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.642E-12 | 7.237E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.074E-11 | 8.664E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.365E-11 | 2.220E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NR1I2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.519E-10 | 4.638E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.040E-08 | 4.923E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.028E-08 | 4.923E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 4.104E-08 | 1.686E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 4.104E-08 | 1.686E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.104E-08 | 1.686E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.368E-07 | 5.228E-05 | AKR1B1, ALDH1A1, CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 5.710E-07 | 1.828E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 5.710E-07 | 1.828E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.148E-06 | 3.333E-04 | CA1, CA12, CA2, CA4, CA6, CA7, CA9, NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 4.193E-06 | 1.014E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.507E-06 | 1.289E-03 | CYP19A1, FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 6.837E-06 | 1.535E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 8.863E-06 | 1.948E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.141E-05 | 2.412E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.197E-05 | 2.506E-03 | ADRA2A, AKR1B1, CA2, CA9, CYP1A2, FFAR4, NPC1, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.450E-05 | 2.871E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.450E-05 | 2.871E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.450E-05 | 2.871E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.764E-05 | 3.370E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 2.013E-05 | 3.747E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.578E-05 | 4.639E-03 | CYP19A1, CYP1A2, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.637E-05 | 4.668E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, FAAH, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.896E-05 | 5.005E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 3.152E-05 | 5.362E-03 | AKR1B1, ALDH1A1, CYP1B1, CYP3A4, NPC1, PPARD |
| CC | GO:0043226; organelle | GO:0043226; organelle | 4.135E-05 | 6.770E-03 | ABCG2, ADRA2C, AKR1B1, ALDH1A1, ALOX15, CA1, CA2, CA4, CA6, CA9, CBR1, CDK6, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, FAAH, FABP5, FFAR4, GAA, HIF1A, HSD17B10, LMNA, MAPT, NPC1, NR1I2, PPARA, PPARD, PPARG, PTGS1, TDP1, TERT, XDH |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 4.733E-05 | 7.691E-03 | ALDH1A1, CYP1A1, CYP1B1, PPARD |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 4.820E-05 | 7.718E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.820E-05 | 7.718E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 5.372E-05 | 8.476E-03 | ADRA2A, AKR1B1, ALOX15, CDK6, CYP1A1, CYP1B1, FFAR4, HIF1A, NPC1, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 5.844E-05 | 9.050E-03 | ADRA2A, CDK6, CYP19A1, FFAR4, HIF1A, LMNA, MAPT, PPARA, PPARD, PPARG, TERT, XDH |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 5.860E-05 | 9.050E-03 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.922E-18 | 2.093E-14 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.483E-18 | 4.276E-16 | CA12; CA1; CA2; CA4; CA7; CA6; CA9; CA14 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.865E-10 | 7.273E-09 | CYP2C9; CBR1; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.290E-10 | 1.115E-08 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.129E-09 | 8.051E-08 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.635E-07 | 2.125E-06 | CBR1; GAA; ALOX15; AKR1B1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C9; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.135E-07 | 2.379E-06 | CYP2C9; CBR1; ALOX15; CYP2C19; PTGS1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.522E-07 | 2.125E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.713E-07 | 2.645E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.667E-07 | 3.178E-06 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.089E-06 | 3.190E-05 | CYP2C9; CYP2D6; ALOX15; CYP2C19; PTGS1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.446E-05 | 1.026E-04 | FABP5; PPARG; PPARA; PPARD |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.652E-05 | 5.191E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.691E-04 | 9.421E-04 | CYP1A1; CYP1B1; CYP19A1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.778E-04 | 2.485E-03 | CA2; CYP3A4; ABCG2 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 5.524E-03 | 2.268E-02 | ADRA2C; ADRA2B; ADRA2A |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.025E-02 | 3.999E-02 | CDK6; PPARG; HIF1A; PPARD |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.401E-03 | 1.907E-02 | CYP3A4; XDH |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.890E-03 | 8.674E-03 | GAA; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.110E-03 | 5.411E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.497E-05 | 2.923E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; ADRA2B |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; ADRA2C; PPARG |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; TERT |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PPARG |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA1; CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ADRA2C |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; ADRA2C |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; NR1I2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; FAAH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; PTGS1; FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; MAPT; PPARG; PPARG |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |